ImmunoPrecise Signs Large Pharma Antibody Development Agreement

Victoria, British Columbia, Canada, October 9th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed an agreement and initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company, to discover novel antibodies using ImmunoPrecise’s proprietary hybridoma technology.

ImmunoPrecise’s hybridoma platform allows for the selection of rare and slow-growing, IgG positive, monoclonal hybridomas in a semi-solid media format. Coupled with proprietary and abbreviated immunization regimes, the ability to sort cells and characterize and optimize lead candidates, ImmunoPrecise’s platform allows for streamlined processes, condensed timelines, and the early identification of developability issues, mitigating the risk of significant losses in time and money.

Under this multi-year development agreement, this global pharmaceutical company receives contract research services using ImmunoPrecise’s methods of discovering and developing antibodies in OmniAb® transgenic animals (Ligand Pharmaceuticals, NASDAQ:LGND), and intellectual property rights to develop and commercialize any resulting therapeutics.

The Agreement stipulates certain confidential provisions, including, at this stage, the pharmaceutical company’s identity, target and the monetary size of contract.

ImmunoPrecise is currently in negotiations with several top 10 global pharmaceutical companies investigating the use of ImmunoPrecise’s three full-service platforms, its advanced hybridoma platform, its proprietary and high demand B-cell selectplatform, and its phage display library platform. All three can be optimally leveraged for antibody discovery using various transgenic and wild-type animal strains.

“ImmunoPrecise can uniquely leverage three powerful platforms for antibody discovery to offer comprehensive campaigns that have the potential to deliver the antibody sequence diversity required to rapidly select the best lead candidates for further advancement” said Jennifer Bath, CEO and President of ImmunoPrecise Antibodies. “We’ve seen very strong interest in our diverse line of development platforms from a number of leading global pharmaceutical and biotech companies. ”

About ImmunoPrecise. ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express and ModiQuest Research, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hyridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

For further information please contact:

 ImmunoPrecise Antibodies Ltd.
Jennifer Bath, CEO and President
3204-4464 Markham Street
Victoria, BC V8Z 7X8

For investor relations please contact: 

Frederick Chabot
Phone: 1-438-863-7071
Contact Financial Corp.
1450 – 701 West Georgia St.
Vancouver, BC V7Y 1G5 

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties.  Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.